IGM Biosciences Inc
NASDAQ:IGMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
IGM Biosciences Inc
NASDAQ:IGMS
|
US |
|
W
|
Wooree E&L Co Ltd
KOSDAQ:153490
|
KR |
|
Adcore Inc
TSX:ADCO
|
CA |
|
C
|
CPT Drives And Power PCL
SET:CPT
|
TH |
|
Home Control International Ltd
HKEX:1747
|
SG |
|
Sendas Distribuidora SA
BOVESPA:ASAI3
|
BR |
|
C
|
Cellcom Israel Ltd
TASE:CEL
|
IL |
IGM Biosciences Inc
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. The company is headquartered in Mountain View, California and currently employs 192 full-time employees. The company went IPO on 2019-09-18. The company has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Financial Strength: IGM ended 2022 with $427.2 million in cash and investments, giving it a cash runway into the second half of 2024.
Clinical Progress: The company launched a randomized Phase 2 trial for IGM-8444 in metastatic colorectal cancer, adding a higher 10 mg/kg dose based on promising biomarker data and FDA feedback.
Strategic Shift: IGM will focus imvotamab development on autoimmune diseases like lupus and rheumatoid arthritis, stopping monotherapy development in non-Hodgkin's lymphoma.
Partnership and Pipeline: The Sanofi collaboration brought $150 million upfront and supports antibody development in both oncology and autoimmunity.
Guidance: 2023 GAAP operating expenses are expected between $290 and $300 million, with guidance to end the year with around $200 million in cash and investments.
Safety & Efficacy: Both IGM-8444 and imvotamab showed encouraging safety profiles and signs of activity in early studies, with imvotamab notable for low rates of cytokine release syndrome.
